The key talking points included Cybin’s Phase 2 study of CYB003, a next-generation treatment for major depressive disorder (MDD). The study revealed extraordinary 12-month efficacy data, including 100% response rates and 71% remission among participants after just two 16 mg doses, administered three weeks apart.

Cybin’s Chief Medical Officer, Amir Inamdar, described the results as “truly remarkable,” highlighting the treatment’s durable, sustained relief and significant improvements in depression scores.

We also delve into Drysdale’s perspective on the industry’s future, particularly in light of Robert Kennedy Jr.’s recent call for more psychedelic research. Additionally, we ask if he feels the industry has recovered from the summer’s Lykos Therapeutics trial news on MDMA.

#cybin #rfk #psychedelics #mentalhealth #psychedelicstocks #depression

Want to see more from Cybin?

   • Why This Quarter Could Be Vital for C...     • Cybin Receives Expedited Review FDA B...  

Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!

https://newsletter.thedalesreport.com...

Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:

Facebook:   / thedalesreport  

Twitter:   / thedalesreport  

Instagram:   / dalesreport  

LinkedIn:   / the-dales-report  

Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...

Spotify: https://tinyurl.com/TDRTradeToBlackon...

Website: https://thedalesreport.com/

For copyright matters, please get in touch with us at:

All views on the Trade To Black podcast and the guests on this podcast are purely opinions. You should not treat any opinions expressed by us or our guests as investment advice. The views on this podcast are solely intended to be informational and are not investment advice. Please go to our website for a full list of disclosures and details of any client relationship we have.

https://thedalesreport.com/website-te...